2023 consensus of Taiwan society of cardiology on the pharmacological treatment of chronic heart failure

Chern En Chiang; Chung Lieh Hung; Yen Wen Wu; Tsung Hsien Lin; Kwo Chang Ueng; Shih Hsien Sung; Cho Ka I. Wu; Ting Hsing Chao; Hung Ju Lin; Yen Hung Lin; Jin Long Huang; Michael Yu Chih Chen; Po Lin Lin; Tze Fan Chao; Hao Min Cheng; Ming En Liu; Tzung Dau Wang; Hung I. Yeh; Yi Heng LI.; Ping Yen Liu; Wei Hsian Yin; I. Chang Hsieh; Chun Chieh Wang; Chen Huan Chen; Pao Hsien Chu; Shing Jong Lin; San Jou Yeh; Jiunn Lee Lin; Juey Jen Hwang; Huei Fong Hung; Wen Jone Chen; Charles Jia Yin Hou

doi:10.6515/ACS.202305_39(3).20230301A

2023 consensus of Taiwan society of cardiology on the pharmacological treatment of chronic heart failure

Chern En Chiang^*, Chung Lieh Hung, Yen Wen Wu, Tsung Hsien Lin, Kwo Chang Ueng, Shih Hsien Sung, Cho Ka I. Wu, Ting Hsing Chao, Hung Ju Lin, Yen Hung Lin, Jin Long Huang, Michael Yu Chih Chen, Po Lin Lin, Tze Fan Chao, Hao Min Cheng, Ming En Liu, Tzung Dau Wang, Hung I. Yeh, Yi Heng LI., Ping Yen LiuWei Hsian Yin, I. Chang Hsieh, Chun Chieh Wang, Chen Huan Chen, Pao Hsien Chu, Shing Jong Lin, San Jou Yeh, Jiunn Lee Lin, Juey Jen Hwang, Huei Fong Hung, Wen Jone Chen, Charles Jia Yin Hou

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

The prevalence of heart failure is increasing, causing a tremendous burden on health care systems around the world. Although mortality rate of heart failure has been significantly reduced by several effective agents in the past 3 decades, yet it remains high in observational studies. More recently, several new classes of drugs emerged with significant efficacy in reducing mortality and hospitalization in chronic heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). To integrate these effective therapies and prioritize them in the management of Asian patients, Taiwan Society of Cardiology has recently appointed a working group to formulate a consensus of pharmacological treatment in patients with chronic heart failure. Based on most updated information, this consensus provides rationales for prioritization, rapid sequencing, and in-hospital initiation of both foundational and additional therapies for patients with chronic heart failure.

Original language	English
Pages (from-to)	361-390
Number of pages	30
Journal	Acta Cardiologica Sinica
Volume	39
Issue number	3
DOIs	https://doi.org/10.6515/ACS.202305_39(3).20230301A
State	Published - May 2023

Keywords

Asia
Chronic heart failure
Consensus
Foundational therapy
Left ventricular ejection fraction

Access to Document

10.6515/ACS.202305_39(3).20230301A

Cite this

Chiang, C. E., Hung, C. L., Wu, Y. W., Lin, T. H., Ueng, K. C., Sung, S. H., Wu, C. K. I., Chao, T. H., Lin, H. J., Lin, Y. H., Huang, J. L., Chen, M. Y. C., Lin, P. L., Chao, T. F., Cheng, H. M., Liu, M. E., Wang, T. D., Yeh, H. I., LI., Y. H., ... Hou, C. J. Y. (2023). 2023 consensus of Taiwan society of cardiology on the pharmacological treatment of chronic heart failure. Acta Cardiologica Sinica, 39(3), 361-390. https://doi.org/10.6515/ACS.202305_39(3).20230301A

@article{ae346fd5fb194ec58f369288a720a31c,

title = "2023 consensus of Taiwan society of cardiology on the pharmacological treatment of chronic heart failure",

abstract = "The prevalence of heart failure is increasing, causing a tremendous burden on health care systems around the world. Although mortality rate of heart failure has been significantly reduced by several effective agents in the past 3 decades, yet it remains high in observational studies. More recently, several new classes of drugs emerged with significant efficacy in reducing mortality and hospitalization in chronic heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). To integrate these effective therapies and prioritize them in the management of Asian patients, Taiwan Society of Cardiology has recently appointed a working group to formulate a consensus of pharmacological treatment in patients with chronic heart failure. Based on most updated information, this consensus provides rationales for prioritization, rapid sequencing, and in-hospital initiation of both foundational and additional therapies for patients with chronic heart failure.",

keywords = "Asia, Chronic heart failure, Consensus, Foundational therapy, Left ventricular ejection fraction",

author = "Chiang, {Chern En} and Hung, {Chung Lieh} and Wu, {Yen Wen} and Lin, {Tsung Hsien} and Ueng, {Kwo Chang} and Sung, {Shih Hsien} and Wu, {Cho Ka I.} and Chao, {Ting Hsing} and Lin, {Hung Ju} and Lin, {Yen Hung} and Huang, {Jin Long} and Chen, {Michael Yu Chih} and Lin, {Po Lin} and Chao, {Tze Fan} and Cheng, {Hao Min} and Liu, {Ming En} and Wang, {Tzung Dau} and Yeh, {Hung I.} and LI., {Yi Heng} and Liu, {Ping Yen} and Yin, {Wei Hsian} and Hsieh, {I. Chang} and Wang, {Chun Chieh} and Chen, {Chen Huan} and Chu, {Pao Hsien} and Lin, {Shing Jong} and Yeh, {San Jou} and Lin, {Jiunn Lee} and Hwang, {Juey Jen} and Hung, {Huei Fong} and Chen, {Wen Jone} and Hou, {Charles Jia Yin}",

year = "2023",

month = may,

doi = "10.6515/ACS.202305_39(3).20230301A",

language = "English",

volume = "39",

pages = "361--390",

journal = "Acta Cardiologica Sinica",

issn = "1011-6842",

publisher = "Republic of China Society of Cardiology",

number = "3",

}

Chiang, CE, Hung, CL, Wu, YW, Lin, TH, Ueng, KC, Sung, SH, Wu, CKI, Chao, TH, Lin, HJ, Lin, YH, Huang, JL, Chen, MYC, Lin, PL, Chao, TF, Cheng, HM, Liu, ME, Wang, TD, Yeh, HI, LI., YH, Liu, PY, Yin, WH, Hsieh, IC, Wang, CC, Chen, CH, Chu, PH, Lin, SJ, Yeh, SJ, Lin, JL, Hwang, JJ, Hung, HF, Chen, WJ & Hou, CJY 2023, '2023 consensus of Taiwan society of cardiology on the pharmacological treatment of chronic heart failure', Acta Cardiologica Sinica, vol. 39, no. 3, pp. 361-390. https://doi.org/10.6515/ACS.202305_39(3).20230301A

TY - JOUR

T1 - 2023 consensus of Taiwan society of cardiology on the pharmacological treatment of chronic heart failure

AU - Chiang, Chern En

AU - Hung, Chung Lieh

AU - Wu, Yen Wen

AU - Lin, Tsung Hsien

AU - Ueng, Kwo Chang

AU - Sung, Shih Hsien

AU - Wu, Cho Ka I.

AU - Chao, Ting Hsing

AU - Lin, Hung Ju

AU - Lin, Yen Hung

AU - Huang, Jin Long

AU - Chen, Michael Yu Chih

AU - Lin, Po Lin

AU - Chao, Tze Fan

AU - Cheng, Hao Min

AU - Liu, Ming En

AU - Wang, Tzung Dau

AU - Yeh, Hung I.

AU - LI., Yi Heng

AU - Liu, Ping Yen

AU - Yin, Wei Hsian

AU - Hsieh, I. Chang

AU - Wang, Chun Chieh

AU - Chen, Chen Huan

AU - Chu, Pao Hsien

AU - Lin, Shing Jong

AU - Yeh, San Jou

AU - Lin, Jiunn Lee

AU - Hwang, Juey Jen

AU - Hung, Huei Fong

AU - Chen, Wen Jone

AU - Hou, Charles Jia Yin

PY - 2023/5

Y1 - 2023/5

N2 - The prevalence of heart failure is increasing, causing a tremendous burden on health care systems around the world. Although mortality rate of heart failure has been significantly reduced by several effective agents in the past 3 decades, yet it remains high in observational studies. More recently, several new classes of drugs emerged with significant efficacy in reducing mortality and hospitalization in chronic heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). To integrate these effective therapies and prioritize them in the management of Asian patients, Taiwan Society of Cardiology has recently appointed a working group to formulate a consensus of pharmacological treatment in patients with chronic heart failure. Based on most updated information, this consensus provides rationales for prioritization, rapid sequencing, and in-hospital initiation of both foundational and additional therapies for patients with chronic heart failure.

AB - The prevalence of heart failure is increasing, causing a tremendous burden on health care systems around the world. Although mortality rate of heart failure has been significantly reduced by several effective agents in the past 3 decades, yet it remains high in observational studies. More recently, several new classes of drugs emerged with significant efficacy in reducing mortality and hospitalization in chronic heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). To integrate these effective therapies and prioritize them in the management of Asian patients, Taiwan Society of Cardiology has recently appointed a working group to formulate a consensus of pharmacological treatment in patients with chronic heart failure. Based on most updated information, this consensus provides rationales for prioritization, rapid sequencing, and in-hospital initiation of both foundational and additional therapies for patients with chronic heart failure.

KW - Asia

KW - Chronic heart failure

KW - Consensus

KW - Foundational therapy

KW - Left ventricular ejection fraction

UR - http://www.scopus.com/inward/record.url?scp=85160652851&partnerID=8YFLogxK

U2 - 10.6515/ACS.202305_39(3).20230301A

DO - 10.6515/ACS.202305_39(3).20230301A

M3 - Article

AN - SCOPUS:85160652851

SN - 1011-6842

VL - 39

SP - 361

EP - 390

JO - Acta Cardiologica Sinica

JF - Acta Cardiologica Sinica

IS - 3

ER -

2023 consensus of Taiwan society of cardiology on the pharmacological treatment of chronic heart failure

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this